Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

STAT News

Rebuffing Trump’s Call for Cuts, Congress Boosts NIH Funding by $2 Billion

Washington, DC, May 1, 2017 — Lev Facher reports in STAT that the National Institutes of Health will get a $2 billion funding boost over the next five months, under a bipartisan spending deal reached late Sunday night in Congress.

The agreement marks a sharp rejection of President Trump’s proposal to cut $1.2 billion from the medical research agency in the current fiscal year.

The deal does not address funding for 2018, when Trump has called for a slashing the NIH’s budget by about a fifth, or $5.8 billion. Continue reading

STAT: PhRMA CEO Says FDA Review Process Is ‘Gold Standard and Should Remain So’

Boston, MA, February 22, 2017 — Rebecca Robbins reports on STAT+ that Stephen Ubl, the President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), yesterday came out strongly in favor of a rigorous Food and Drug Administration (FDA).

Ubl’s remarks come as the Trump administration weighs potential candidates to lead the agency who have suggested they would radically change how it vets new drugs.

Asked by STAT about the notion that the FDA should no longer evaluate drugs for effectiveness, Ubl was unambiguous: “We believe that the FDA review process is the gold standard and should remain so.” Continue reading

STAT News: Six Former Commissioners Say FDA Should Be Independent Agency

FDA blueWashington, DC, June 28, 2016 ― Give the FDA independence and elevate its status.  That’s the message from six former commissioners who led the FDA for a combined 32 years, reports Helen Branswell on STAT News.

The FDA is currently part of the Department of Health and Human Services (HHS). Making it a Cabinet-level organization or finding another way to give it more autonomy would be a step in the right direction for public health, the former commissioners argued.

The newly confirmed FDA commissioner, Dr. Robert Califf, listened to their arguments but declined to comment on their call to elevate the stature of the FDA. Continue reading

Obama Administration to Launch Microbiome Initiative, Heeding Scientists’ Calls

STATWashington, DC, May 13 ― The White House is set to launch a new national program Friday to study microbiomes found on the human body and across different ecosystems, following calls from scientists to unlock the secrets of the microbes that have a big impact on people’s health and the environment, reports David Nather on STAT News.

The new National Microbiome Initiative will start with a federal investment of $121 million in funding from several agencies and will include private support from more than 100 outside organizations, including $100 million over four years from the Bill and Melinda Gates Foundation, according to a White House fact sheet that was posted online on Thursday.

The new initiative is the latest in a series of Obama administration programs to advance medical science. It has already launched the Precision Medicine Initiative, which is trying to accelerate research into treatments tailored to individual patients; the BRAIN Initiative, the project to map the human brain; and Vice President Joe Biden’s cancer research effort, which is now getting underway. Continue reading

STAT News: Interview with PhRMA CEO: The One Drug Pricing Idea Clinton and PhRMA Can Agree On

Stephen J. Ubl

Stephen J. Ubl

Washington, DC, April 12 ― The pharmaceutical industry has opposed most of Secretary of State Hillary Clinton’s proposals to bring down drug costs, but there’s one idea its chief lobbyist supports: limiting the amount that consumers have to pay out of their own pockets, reports David Nather on STAT.

In an interview with STAT, Stephen J. Ubl, president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), the main trade group for drug companies, singled out the proposal when asked whether there were any positive ideas in the Democratic presidential front-runner’s drug prices plan.

“I would say one thing that she has proposed that we would favor is capping out-of-pocket costs,” Ubl said.  “I think we have to acknowledge that some patients do face challenges in accessing their medicines.” Continue reading